New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
14:17 EDTDVAXDynavax volatility elevated into PDUFA
Dynavax overall option implied volatility of 137 is above its 26-week average of 97 according to Track Data, suggesting larger price movement into PDUFA Date for Heplisav in late February.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
06:02 EDTDVAXDynavax completes enrollment of HEPLISAV-B Phase 3 study
Dynavax Technologies announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S. This large safety and immunogenicity study is intended to provide an adequately-sized database of vaccinated subjects to enable the FDA to complete its review of the pending HEPLISAV-B Biologics License Application. The study is also designed to assess the immunogenicity of HEPLISAV-B in adults for whom approved hepatitis B vaccines are less effective, including those with type-2 diabetes mellitus.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use